No current therapy specifically targets diabetes-induced CVD, however, promising immunization strategies against AS have been developed [2-9], supported by: association between autoantibodies against oxidized plasma low density lipoprotein (ox-LDL) and AS in humans [10]; reduced AS lesion formation in mice after ox-LDL immunization [11]; and AS regression induction in Apobec-1−/− /LDL receptor (LDLR) null mice by recombinant antibodies against aldehyde-modified apoB100 peptide 661–680 [12]. Here, LDLR is linked to diabetes mellitus.